Contrasting Profound Medical (NASDAQ:PROF) and Cosmos Health (NASDAQ:COSM)

Cosmos Health (NASDAQ:COSM) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Earnings and Valuation

This table compares Cosmos Health and Profound Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cosmos Health	$59.79 million	0.20	-$16.18 million	($0.75)	-0.43
Profound Medical	$16.10 million	14.72	-$42.57 million	($1.41)	-4.63

Cosmos Health has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cosmos Health and Profound Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cosmos Health	-31.01%	-33.19%	-13.65%
Profound Medical	-264.45%	-90.28%	-73.94%

Volatility and Risk

Cosmos Health has a beta of 5.39, meaning that its stock price is 439% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cosmos Health and Profound Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cosmos Health	1	0	0	0	1.00
Profound Medical	1	0	1	0	2.00

Profound Medical has a consensus price target of $12.00, indicating a potential upside of 83.77%. Given Profound Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than Cosmos Health.

Institutional and Insider Ownership

12.6% of Cosmos Health shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 25.1% of Cosmos Health shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cosmos Health beats Profound Medical on 9 of the 14 factors compared between the two stocks.

About Cosmos Health

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.